The PD-1/PD-L1 axis plays a prominent role in immune suppression of the tumour microenvironment [40, 41], and patients with higher tumour PD-L1 expression achieve improved responses to treatment with anti-PD-1 and anti-PD-L1 therapy, compared with patients with lower PD-L1 expression. Here, CD274 is linked to neoplasm.